Get started
Author

Roni Nitecki Wilke

Observed name: Roni Wilke
OpenAlex ID: A5133769753
Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial
2026 · Roni Nitecki Wilke, Haley A. Moss, et al. · Journal of Clinical Oncology · 1
ACT-ON: Assisted cascade testing via outreach and navigation – Real-world experience with clinician-facilitated cascade testing
2026 · Emily S. Epstein, Michelle Primiano, et al. · Gynecologic Oncology · 1
Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2
2026 · Isabel Beshar, David Viveros-Carreño, et al. · JAMA Network Open
PDF
Robotic Compared to Laparoscopic Interval Cytoreductive Surgery in Stage Iii Ovarian Cancer: an Analysis of the National Cancer Database
2026 · Gabriel Levin, Nuria Agusti, et al. · International Journal of Gynecological Cancer
Occult Nodal Metastasis in Apparent Early Low-grade Serous Ovarian Carcinoma: a Meta Analysis.
2026 · David Viveros-Carreño, Nuria Agusti, et al. · International Journal of Gynecological Cancer
Postoperative Shivering May Represent Promethazine Associated Extrapyramidal Symptoms Rather Than Hypothermia in an Enhanced Recovery Cohort
2026 · Javier Lasala, Jose M. Soliz, et al. · Clinical Nutrition ESPEN
Perioperative Ketamine Is Associated With Attenuated Postoperative Inflammatory Response and Delayed Gastrointestinal Recovery in an Enhanced Recovery Cohort
2026 · Javier Lasala, Jose M. Soliz, et al. · Clinical Nutrition ESPEN
International trends in concurrent hysterectomy at risk-reducing surgery in BRCA1/2 pathogenic variant carriers: a mixed-methods study
2026 · Tamar A. Gootzen, Barbara M. Norquist, et al. · American Journal of Obstetrics and Gynecology
Clinician-facilitated cascade genetic testing among first-, second-, and third-degree relatives.
2026 · Steve Lopez, Lauren Davis Rivera, et al. · Journal of Clinical Oncology
PDF
Phase II investigation of pembrolizumab in combination with bevacizumab and oral cyclophosphamide in patients with high grade ovarian cancer and surgical or molecular minimal residual disease after frontline therapy
2026 · Travis Sims, Anne Knisely, et al. · Gynecologic Oncology
Adherence to guideline-directed timing of risk-reducing surgery for women at increased risk of hereditary tubo-ovarian cancer
2026 · Eliane Aoun, Ana Lopez, et al. · Gynecologic Oncology
Tubo-ovarian cancer incidence among breast cancer patients with hereditary breast and ovarian cancer: An analysis of the surveillance, epidemiology and end results registry
2026 · Isabel Beshar, Chi-Fang Wu, et al. · Gynecologic Oncology
ACT-ON: Assisted cascade testing via outreach and navigation – Real-world experience with clinician-facilitated cascade testing
2026 · Melissa Frey, Emily Epstein, et al. · Gynecologic Oncology
Metachronous breast cancer among women with ovarian cancer and germline BRCA1/2 pathogenic variants: A population-based analysis
2026 · Maria Iniesta, Nuria Agusti, et al. · Gynecologic Oncology
Combination PP2A inhibition and PD-1 blockade with LB-100 and dostarlimab in ovarian clear cell carcinoma
2026 · Helen Clark, Emily Hinchcliff, et al. · Gynecologic Oncology
Integrating circulating tumor DNA and second-look laparoscopy for minimal residual disease detection and survival prediction in ovarian cancer
2026 · Helen Clark, Sanghoon Lee, et al. · Gynecologic Oncology
IGNITE-TX (identifying individuals for genetic testing & treatment): A feasibility randomized trial
2026 · Kirsten Jorgensen, Nuria Agusti, et al. · Gynecologic Oncology
A randomized feasibility study of group-based education intervention for BRCA1/2 pathogenic variant carriers
2026 · Isabel Beshar, Alexa Kanbergs, et al. · Gynecologic Oncology
Treatment outcomes with checkpoint inhibitors in recurrent gestational trophoblastic neoplasia
2026 · Alissa Chebat, David Gershenson, et al. · Gynecologic Oncology
Works count: 19
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type